Abstract
BackgroundWe previously reported that interstitial injection of bleomycin (BLM) reduces the size of early-stage extracranial arteriovenous malformation (AVM). Here, we sought to investigate the potential mechanism of BLM in treating extracranial AVM. MethodsSamples of human extracranial AVM (n=3) with no pharmacological treatment were harvested. AVM endothelial cells were isolated and cultured in primary cell culture. The transcriptome was examined using RNA-sequencing, and differentially expressed C-type lectin domain family 14 member A (CLEC14A) was validated at the transcriptomic and protein levels. Immunocytochemical staining of CLEC14A was performed in samples of human extracranial AVM, with and without BLM treatment. ResultsThrough second-generation sequencing, we found that the expression of 5 689 genes were differentially increased or decreased following 24-h BLM stimulation. We found that CLEC14A may play an important role in the progression of AVM and can be inhibited by BLM treatment. ConclusionBLM inhibited CLEC14A expression to attenuate the progression of AVM.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Chinese Journal of Plastic and Reconstructive Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
